Two HIV patients who received an experimental immune cell therapy have shown signs of long-term virus control after stopping standard antiretroviral drugs. The early-stage findings offer a potential new path toward managing HIV without daily medication.
The approach uses CAR-T cell therapy, a treatment already approved for certain blood cancers. Scientists engineer a patient’s own T cells to better recognize and attack infected cells. In this case, the modified cells were designed to target HIV reservoirs hiding in the body.
Both participants in the small study remained on antiretroviral therapy for years before receiving the modified cells. After treatment, they stopped their regular HIV medication to test whether the engineered cells could keep the virus in check.
One participant kept HIV levels undetectable for more than two years without any antiretroviral drugs. The other experienced a viral rebound after a few months but regained control after restarting and then stopping treatment again.
The results mark the first demonstration of sustained viral control after a single infusion of CAR-T cells. Researchers stress the findings remain preliminary and require confirmation in larger, more diverse groups.
HIV persists because it hides in latent reservoirs that standard drugs cannot reach. CAR-T therapy aims to flush out those reservoirs and destroy infected cells more effectively than the immune system can alone.
Current HIV management requires lifelong daily pills or regular injections. A therapy that could offer extended periods without treatment would significantly improve quality of life for millions living with the virus.
The study builds on years of research adapting CAR-T technology from oncology to infectious disease. Scientists note that HIV presents unique challenges because the virus mutates rapidly and actively attacks immune cells.
Further trials must address safety and determine the ideal timing for stopping antiretroviral drugs. Researchers are also exploring ways to make the engineered cells persist longer in the body.
While a cure remains distant, these early signs suggest CAR-T therapy could eventually provide a functional cure for HIV. Such a treatment would suppress the virus indefinitely without requiring daily medication.
